ArticleThe European respiratory journal2022
Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients.
Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Biologic Therapies and Biomarkers in Severe Childhood Asthma: A Systematic Review of Omalizumab and Mepolizumab.Pediatric pulmonology · 2026Pooled it
- The Clinical and Economic Impact of Biologic Agents in Asthma Management: a Systematic Review.Lung · 2026Pooled it
- Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials.BMC pediatrics · 2026Pooled it
- Pediatric spontaneous-reporting patterns for biologics approved or used for asthma: Analysis of the FDA adverse event reporting system.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- The identification of biomarkers for response to omalizumab in adult asthma based on untargeted metabolomic analysis.Medicine · 2026Article
- Age-specific efficacy of biologics in severe asthma: a pediatric perspective.Frontiers in allergy · 2026Review
- Clinical and Cost-Effectiveness of Omalizumab in Concomitant Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Real-World Exploratory Study.Journal of asthma and allergy · 2026Article
- Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection.Frontiers in allergy · 2026Review
- Predictive Factors And Treatments Associated with Clinical Remission in Severe Eosinophilic Asthma.Journal of inflammation research · 2026Review
- Drug survival of omalizumab in atopic asthma: Impact of clinical and genetic variables.Human vaccines & immunotherapeutics · 2025Observational
- Discontinuation of biologic therapy in severe asthma: Evidence and strategies for safe withdrawal: A scoping review.The World Allergy Organization journal · 2025Review
- Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients.Yonsei medical journal · 2025Article
- Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group.Children (Basel, Switzerland) · 2025Review
- Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab.Journal of personalized medicine · 2025Article
- Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthma.Frontiers in allergy · 2025Article
- Clinical, functional, and laboratory course of children and adolescents with severe asthma after discontinuation of biologics.Frontiers in allergy · 2025Article
- Biologics in severe asthma: a state-of-the-art review.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Transition of care from adolescence to early adulthood in severe asthmatic patients treated with omalizumab in real life.ERJ open research · 2024Article
- The Incredible Adventure of Omalizumab.International journal of molecular sciences · 2024Review
- The Evolution of Scientific Knowledge in Childhood Asthma over Time: A Surprising History.Children (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis real-life study aimed to assess omalizumab treatment patterns in adult and paediatric asthma patients, and to describe asthma control and healthcare resource use (HCRU) at omalizumab initiation and discontinuation.
methodsThe French healthcare database system (Système National des Données de Santé (SNDS)) was used to identify asthma patients aged ≥6 years who initiated omalizumab for at least 16 weeks from 2009 to 2019. We examined omalizumab treatment patterns using dispensation records.
resultsWe identified 16 750 adults and 2453 children initiating omalizumab. Median treatment persistence before discontinuation (T
conclusionThis is the first large-scale study describing omalizumab real-life exposure patterns in adult and paediatric asthma patients in France with >10 years of follow-up. We showed the long-term maintenance of low HCRU in adults and children who discontinued omalizumab while asthma was controlled, notably for OCS use and hospitalisations for asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.